Form 4: Esperion Therapeutics Director Stephen Rocamboli Increases Stake with Significant Equity Awards

Esperion Therapeutics, Inc. Director Stephen Rocamboli acquired 33,000 shares of common stock and 44,000 stock options on May 29, 2025, significantly increasing his beneficial ownership in the company.

Summary

• Stephen Rocamboli, a Director of Esperion Therapeutics, Inc. (ESPR), reported changes in his beneficial ownership through a Form 4 filing.
• On May 29, 2025, Mr. Rocamboli acquired 33,000 shares of common stock at a price of $0 per share.
• Following this transaction, his direct beneficial ownership of common stock increased to 69,261 shares.
• Concurrently, he also acquired 44,000 stock options with an exercise price of $0.87 per share, also at a price of $0.
• The acquired stock and option awards are scheduled to vest in full on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director, especially at a $0 cost (indicating a grant), is generally a positive signal as it aligns management's interests with shareholders and suggests confidence in the company's future. The transaction being under a 10b5-1 plan also indicates proper governance.

Positives

• Director Stephen Rocamboli increased his beneficial ownership in Esperion Therapeutics, acquiring 33,000 shares of common stock and 44,000 stock options, signaling confidence in the company's future.
• The acquisition of stock and options at a $0 price indicates these are likely equity awards (e.g., grants, compensation), which aligns management's interests with those of shareholders.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, demonstrating a structured and compliant approach to insider trading.

Future Outlook

The acquired stock and option awards are subject to a vesting schedule, with full vesting occurring on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025. This indicates a future milestone for the full realization of these equity incentives.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction within the biotechnology/pharmaceutical industry. Such equity awards are a common component of executive compensation packages, designed to align the interests of directors and executives with long-term shareholder value creation. The filing itself does not provide broader industry trends but reflects typical corporate governance practices for public companies like Esperion Therapeutics.

Comparison to Industry Standards

• The granting of stock and stock options as part of director compensation is a common practice across the biotechnology and pharmaceutical industries, aligning executive incentives with company performance.
• The use of a Rule 10b5-1 plan for such transactions is an industry standard for insiders to manage their equity holdings compliantly and avoid accusations of insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: The increase in director ownership through equity awards can be viewed positively as it aligns management's incentives with shareholder value creation and demonstrates confidence in the company's prospects.

Next Steps

• The acquired common stock and stock options will vest on the earlier of May 29, 2026, or the Issuer's next annual meeting of stockholders following May 29, 2025.

Key Dates

Keywords

Esperion Therapeutics, ESPR, Form 4, Insider Transaction, Stock Acquisition, Stock Options, Beneficial Ownership, Director, Equity Awards, Rule 10b5-1